Thanks to the sustained pressure of our campaign, pharmaceutical company, Gilead, has increased the supply of Trodelvy available through their pre-reimbursement access scheme.
Gilead is now confident that they will be able to supply all eligible women with triple negative secondary breast cancer (TNSBC) who need the treatment, free of charge, until May when we expect a decision about its routine use on the NHS to be announced.
Previously their scheme had been limited and worked on a first come, first served basis, meaning patients could have missed out.
Every one of the 228,309 people who signed the petition helped pressure Gilead into increasing the supply of their scheme. So, thank you! Together, we’ve brought hope to people living with triple negative secondary breast cancer.